SGLT2 inhibitors are also involved in inhibiting sodium–phosphate co-transporter 2a, a PT transporter involved in phosphate reabsorption, resulting in hyperphosphataemia and elevated levels of fibroblast growth factor-23 and PTH [109, 110], which might worsen mineral and bone disorder in CKD patients. This evidence concerns the gene SLC5A2 and chronic kidney disease.